EU Approves Tryngolza for Severe Hypertriglyceridaemia
The olezarsen therapy is the first RNA-targeted treatment authorised in the EU for this condition at the 880 mg/dL threshold.
Updated on Nov. 17, 2026 in Heart Disease

The European Commission approved Tryngolza (olezarsen) as an adjunct to diet and other lipid-lowering therapies for adults with severe hypertriglyceridaemia and fasting triglyceride levels of at least 880 mg/dL (10 mmol/L). The approval follows a positive opinion from the Committee for Medicinal Products for Human Use and expands the existing indication for familial chylomicronaemia syndrome.
Why it matters
Patients with triglyceride levels of at least 880 mg/dL are considered at high risk of developing acute pancreatitis, and the approval extends a targeted option to a broader patient population. The decision brings an RNA-targeted therapy to patients who previously had limited options at this threshold.
The approval rests on phase 3 CORE and CORE2 trial data, which showed triglyceride reductions of up to 73% versus placebo at six months, maintained for 12 months. A pooled analysis reported an 83% reduction in acute pancreatitis events versus placebo over 12 months, though the source does not detail results beyond that window.
The players
Ionis Pharmaceuticals
Ionis Pharmaceuticals is a biotechnology company that sponsored the phase 3 CORE and CORE2 studies supporting the approval, and it develops RNA-targeted medicines.
Sobi
Sobi is a specialty healthcare company that is involved in the commercialisation of Tryngolza in the European market.
The details
The European Commission granted approval after the Committee for Medicinal Products for Human Use issued a positive opinion, with the CHMP opinion issued in October. The approval is based on the phase 3 CORE and CORE2 studies, and it is estimated that approximately 700,000 people across the EU's five largest markets have triglyceride levels of at least 880 mg/dL.
Timeline
October 2026: The CHMP issued a positive opinion on Tryngolza.
17 November 2026: The European Commission approved Tryngolza for severe hypertriglyceridaemia.
Health Landscape
The approval follows the standard EU pathway in which a CHMP positive opinion precedes a European Commission decision, extending the existing familial chylomicronaemia syndrome indication for Tryngolza into a wider severe hypertriglyceridaemia population. It positions olezarsen as the first RNA-targeted therapy authorised in the EU for sHTG at the 880 mg/dL threshold.
Adults with triglyceride levels of at least 880 mg/dL in the EU may now have access to a targeted treatment as an add-on to diet and other lipid-lowering therapies. Patients and clinicians should consult their physicians about whether this option is appropriate given individual risk and existing treatment.
The takeaway
Triglyceride levels at or above 880 mg/dL carry a high risk of acute pancreatitis, so patients in this range should discuss targeted treatment options with their physicians. The 12-month durability of triglyceride reductions reported in the trials is a useful point for those weighing long-term management.
Further reading
Explore related coverage in the Heart Disease section for more context on cardiovascular and lipid-related conditions.







